Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 3;29(2):433-441.
doi: 10.1016/j.ymthe.2020.10.022. Epub 2020 Oct 31.

Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies

Mark B Leick  1 , Marcela V Maus  2 , Matthew J Frigault  1
Affiliations
Review

Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies

Mark B Leick et al. Mol Ther. .

Abstract

Large B cell lymphoma (LBCL) is curable with standard chemo-immunotherapy in the majority of cases. However, patients with primary refractory or relapsed disease have historically had limited treatment options. Two gene-modified chimeric antigen receptor (CAR)-T cell therapies have now been approved for these indications. The clinical decisions and management surrounding these gene-modified "living drugs" are nuanced and complex. In this article, we discuss the evolving evidence supporting the use of these CAR-T cells, including patient selection, screening procedures, special populations, bridging therapy, lymphodepletion, clinical management, relapse, and follow up.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest M.J.F. and M.V.M. have received sponsored research support from Kite Pharma and Novartis and are investigators and consultants on multiple industry-sponsored trials of CAR-T cells. M.V.M. holds equity in Century Therapeutics and TCR2.

Figures

None
Graphical abstract
Figure 1
Figure 1
Flowchart of Management Considerations
Figure 2
Figure 2
Timeline of CAR-T Cell Treatment at Our Institution
See this image and copyright information in PMC

References

    1. Union for International Camcer Control . 2014. Diffuse Large B-Cell Lymphoma. 2014 Review of Cancer Medicines on the WHO List of Essential medicines.https://www.who.int/selection_medicines/committees/expert/20/application...
    1. Coiffier B., Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology (Am. Soc. Hematol. Educ. Program) 2016;2016:366–378. - PMC - PubMed
    1. Van Den Neste E., Schmitz N., Mounier N., Gill D., Linch D., Trneny M., Bouadballah R., Radford J., Bargetzi M., Ribrag V. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52:216–221. - PubMed
    1. Crump M., Neelapu S.S., Farooq U., Van Den Neste E., Kuruvilla J., Westin J., Link B.K., Hay A., Cerhan J.R., Zhu L. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808. - PMC - PubMed
    1. Locke F.L., Ghobadi A., Jacobson C.A., Miklos D.B., Lekakis L.J., Oluwole O.O. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018 - PMC - PubMed

Substances

LinkOut - more resources